{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"ara-290-glp1-agonists","title":"ARA-290 × GLP-1 agonists (class)","body":"## ARA-290 and glp1 agonists — where repair fits\nglp1 agonists represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether ara-290 mechanisms address underlying repair deficits.\n\n## What is known about ARA-290 with glp1 agonists\nStudied for nerve repair and small-fiber regeneration in neuropathy models.\n\nTarget condition: glp1 agonists.\nBody system: Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss..\n\n## Logic chain — ARA-290 to glp1 agonists\n1. ara-290 studied for nerve repair and small-fiber regeneration in neuropathy models..\n2. glp1 agonists involves metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss. dysfunction.\n3. If ara-290 reaches the affected tissue, it may shift the repair/breakdown balance.\n4. This chain is tested in animal or lab models only.\n\n## ARA-290 parent claims that bear on glp1 agonists\n- ARA-290 is an 11-amino-acid peptide engineered from erythropoietin that selectively activates the innate repair receptor (IRR).\n- In phase 2 trials, ARA-290 reduced neuropathic symptoms and improved quality of life in sarcoidosis small fiber neuropathy patients.\n- ARA-290 treatment increased corneal nerve fiber density in sarcoidosis patients with initial reductions.\n- In rodent sciatic and spared nerve injury models, ARA-290 reduced allodynia in a β-common receptor-dependent manner.\n- Commercial vendors and clinics market this compound (17 commercial/clinic sources catalogued) — marketing material, not evidence.\n\n## Evidence tier for ARA-290 with glp1 agonists\nPreclinical — animal and in vitro studies only. No published human trials for this specific combination.\n\n## What we do not know about ARA-290 with glp1 agonists\n- Whether ara-290 reaches glp1 agonists tissue at functional concentrations\n- Optimal dosing, route, and duration for this target\n- Interaction with standard-of-care treatments for glp1 agonists\n- Long-term safety profile in this population\n\n## Safety note\n\nAll peptide use for glp1 agonists is research-context only. Not medical advice. Consult a physician before any experimental compound.","hero":null,"images":[],"style":{},"tags":["peptide"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/ara-290-glp1-agonists/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[],"sources":[],"reviews":[],"extra":{},"has_traversal":false,"register":"standard","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T18:34:49.681Z","model":"grok-4.3","role":"writer","action":"draft","payload":{"title":"ARA-290 × GLP-1 agonists (class)","register":"standard","body":"## Overview\nEvidence is being populated by Grok web search.","claims":[],"sources":[]},"rationale":"","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"genesis","hash":"9238c6c58916d3a6cd691c6dc7505bad0467cf6b62ec40c4c10847763e96212d"}],"provenance":[{"ts":"2026-06-29T18:34:49.681Z","model":"grok-4.3","action":"populate-init","prompt":"","input":"","response":"","tokens_in":0,"tokens_out":0,"cost":0,"prev":"genesis","hash":"e2519918b4e3852be2e24cd5de654ee05c4a5a14ddbbd17069b32d646984ae71"},{"ts":"2026-07-17T02:38:12.395Z","model":"owner","action":"voxel_divide","prompt":"","input":"ara-290-glp1-agonists","response":"15 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"e2519918b4e3852be2e24cd5de654ee05c4a5a14ddbbd17069b32d646984ae71","hash":"de6c5ed5478e478d94b8a5e39268ac214a6e2b20656dff9fc0ab6c7485b6ac38"}],"energy":{"passes":2,"tokens_in":0,"tokens_out":0,"tokens_total":0,"cost_usd":0,"models":{"grok-4.3":1,"owner":1},"head":"de6c5ed5478e478d94b8a5e39268ac214a6e2b20656dff9fc0ab6c7485b6ac38"},"posted_at":"2026-06-29T18:34:49.681Z","created_at":"2026-06-29T18:34:49.681Z","updated_at":"2026-08-08T04:23:00.727Z","machine":{"shape":"article.machine/v1","slug":"ara-290-glp1-agonists","kind":"article","read":{"human":"https://miscsubjects.com/a/ara-290-glp1-agonists","json":"https://miscsubjects.com/api/articles/ara-290-glp1-agonists","bundle":"https://miscsubjects.com/api/articles/ara-290-glp1-agonists/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":0,"sources":0,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/ara-290-glp1-agonists/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=ara-290-glp1-agonists","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"ara-290-glp1-agonists\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"ara-290-glp1-agonists\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/ara-290-glp1-agonists/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"ara-290-glp1-agonists\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/ara-290-glp1-agonists | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/ara-290-glp1-agonists","json":"/api/articles/ara-290-glp1-agonists","markdown":"/api/articles/ara-290-glp1-agonists/bundle?format=markdown","skill":"/api/articles/ara-290-glp1-agonists/skill","topology":"/api/articles/ara-290-glp1-agonists/topology","versions":"/api/articles/ara-290-glp1-agonists/revisions","invocations":"/api/articles/ara-290-glp1-agonists/invocations"},"editorial_review":null,"editorial_audit":{"slug":"ara-290-glp1-agonists","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"4d972f32d33fd47a926156c73167bac8d86b450d09bdd4ab77c4d0e37f756890","object":{"object_type":"article-object","identity":{"id":"article:ara-290-glp1-agonists","slug":"ara-290-glp1-agonists","title":"ARA-290 × GLP-1 agonists (class)"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/ara-290-glp1-agonists","role":"explain","audience":"human"},"skill":{"route":"/api/articles/ara-290-glp1-agonists/skill","role":"direct behavior","audience":"model","content":"---\nname: ara-290-glp1-agonists\ndescription: Apply the ARA-290 × GLP-1 agonists (class) article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# ARA-290 × GLP-1 agonists (class)\n\nThis Skill is the behavioral expression of [the canonical article](/a/ara-290-glp1-agonists). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/ara-290-glp1-agonists.\n- Read claims and relationships at /api/articles/ara-290-glp1-agonists/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nARA-290 and glp1 agonists — where repair fits glp1 agonists represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether ara-290 mechanisms address underlying repair deficits. What\n\n## Representations\n\n- Human: /a/ara-290-glp1-agonists\n- JSON: /api/articles/ara-290-glp1-agonists\n- Relationships: /api/articles/ara-290-glp1-agonists/topology\n- History: /api/articles/ara-290-glp1-agonists/revisions\n"},"json":{"route":"/api/articles/ara-290-glp1-agonists","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/ara-290-glp1-agonists/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","ara","290","glp1","agonists"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/ara-290-glp1-agonists/invocations?status=success","failure_events":"/api/articles/ara-290-glp1-agonists/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"ara-290-glp1-agonists","title":"ARA-290 × GLP-1 agonists (class)","body":"## ARA-290 and glp1 agonists — where repair fits\nglp1 agonists represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether ara-290 mechanisms address underlying repair deficits.\n\n## What is known about ARA-290 with glp1 agonists\nStudied for nerve repair and small-fiber regeneration in neuropathy models.\n\nTarget condition: glp1 agonists.\nBody system: Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss..\n\n## Logic chain — ARA-290 to glp1 agonists\n1. ara-290 studied for nerve repair and small-fiber regeneration in neuropathy models..\n2. glp1 agonists involves metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss. dysfunction.\n3. If ara-290 reaches the affected tissue, it may shift the repair/breakdown balance.\n4. This chain is tested in animal or lab models only.\n\n## ARA-290 parent claims that bear on glp1 agonists\n- ARA-290 is an 11-amino-acid peptide engineered from erythropoietin that selectively activates the innate repair receptor (IRR).\n- In phase 2 trials, ARA-290 reduced neuropathic symptoms and improved quality of life in sarcoidosis small fiber neuropathy patients.\n- ARA-290 treatment increased corneal nerve fiber density in sarcoidosis patients with initial reductions.\n- In rodent sciatic and spared nerve injury models, ARA-290 reduced allodynia in a β-common receptor-dependent manner.\n- Commercial vendors and clinics market this compound (17 commercial/clinic sources catalogued) — marketing material, not evidence.\n\n## Evidence tier for ARA-290 with glp1 agonists\nPreclinical — animal and in vitro studies only. No published human trials for this specific combination.\n\n## What we do not know about ARA-290 with glp1 agonists\n- Whether ara-290 reaches glp1 agonists tissue at functional concentrations\n- Optimal dosing, route, and duration for this target\n- Interaction with standard-of-care treatments for glp1 agonists\n- Long-term safety profile in this population\n\n## Safety note\n\nAll peptide use for glp1 agonists is research-context only. Not medical advice. Consult a physician before any experimental compound.","hero":null,"images":[],"style":{},"tags":["peptide"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/ara-290-glp1-agonists/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[],"sources":[],"reviews":[],"extra":{},"has_traversal":false,"register":"standard","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T18:34:49.681Z","model":"grok-4.3","role":"writer","action":"draft","payload":{"title":"ARA-290 × GLP-1 agonists (class)","register":"standard","body":"## Overview\nEvidence is being populated by Grok web search.","claims":[],"sources":[]},"rationale":"","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"genesis","hash":"9238c6c58916d3a6cd691c6dc7505bad0467cf6b62ec40c4c10847763e96212d"}],"provenance":[{"ts":"2026-06-29T18:34:49.681Z","model":"grok-4.3","action":"populate-init","prompt":"","input":"","response":"","tokens_in":0,"tokens_out":0,"cost":0,"prev":"genesis","hash":"e2519918b4e3852be2e24cd5de654ee05c4a5a14ddbbd17069b32d646984ae71"},{"ts":"2026-07-17T02:38:12.395Z","model":"owner","action":"voxel_divide","prompt":"","input":"ara-290-glp1-agonists","response":"15 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"e2519918b4e3852be2e24cd5de654ee05c4a5a14ddbbd17069b32d646984ae71","hash":"de6c5ed5478e478d94b8a5e39268ac214a6e2b20656dff9fc0ab6c7485b6ac38"}],"energy":{"passes":2,"tokens_in":0,"tokens_out":0,"tokens_total":0,"cost_usd":0,"models":{"grok-4.3":1,"owner":1},"head":"de6c5ed5478e478d94b8a5e39268ac214a6e2b20656dff9fc0ab6c7485b6ac38"},"posted_at":"2026-06-29T18:34:49.681Z","created_at":"2026-06-29T18:34:49.681Z","updated_at":"2026-08-08T04:23:00.727Z","machine":{"shape":"article.machine/v1","slug":"ara-290-glp1-agonists","kind":"article","read":{"human":"https://miscsubjects.com/a/ara-290-glp1-agonists","json":"https://miscsubjects.com/api/articles/ara-290-glp1-agonists","bundle":"https://miscsubjects.com/api/articles/ara-290-glp1-agonists/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":0,"sources":0,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/ara-290-glp1-agonists/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=ara-290-glp1-agonists","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"ara-290-glp1-agonists\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"ara-290-glp1-agonists\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/ara-290-glp1-agonists/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"ara-290-glp1-agonists\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/ara-290-glp1-agonists | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/ara-290-glp1-agonists","json":"/api/articles/ara-290-glp1-agonists","markdown":"/api/articles/ara-290-glp1-agonists/bundle?format=markdown","skill":"/api/articles/ara-290-glp1-agonists/skill","topology":"/api/articles/ara-290-glp1-agonists/topology","versions":"/api/articles/ara-290-glp1-agonists/revisions","invocations":"/api/articles/ara-290-glp1-agonists/invocations"},"editorial_review":null,"editorial_audit":{"slug":"ara-290-glp1-agonists","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"4d972f32d33fd47a926156c73167bac8d86b450d09bdd4ab77c4d0e37f756890"}}}